| First Author | Wu CY | Year | 2020 |
| Journal | J Immunol | Volume | 205 |
| Issue | 1 | Pages | 202-212 |
| PubMed ID | 32482710 | Mgi Jnum | J:292462 |
| Mgi Id | MGI:6444987 | Doi | 10.4049/jimmunol.1900284 |
| Citation | Wu CY, et al. (2020) IgA Nephropathy Benefits from Compound K Treatment by Inhibiting NF-kappaB/NLRP3 Inflammasome and Enhancing Autophagy and SIRT1. J Immunol 205(1):202-212 |
| abstractText | IgA nephropathy (IgAN), the most common primary glomerular disorder, has a relatively poor prognosis yet lacks a pathogenesis-based treatment. Compound K (CK) is a major absorbable intestinal bacterial metabolite of ginsenosides, which are bioactive components of ginseng. The present study revealed promising therapeutic effects of CK in two complementary IgAN models: a passively induced one developed by repeated injections of IgA immune complexes and a spontaneously occurring model of spontaneous grouped ddY mice. The potential mechanism for CK includes 1) inhibiting the activation of NLRP3 inflammasome in renal tissues, macrophages and bone marrow-derived dendritic cells, 2) enhancing the induction of autophagy through increased SIRT1 expression, and 3) eliciting autophagy-mediated NLRP3 inflammasome inhibition. The results support CK as a drug candidate for IgAN. |
